{"id":"treatment-c","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Aspirin","action":"Avoid","effect":"Increased risk of bleeding"},{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ibuprofen","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Clopidogrel","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Pentoxifylline","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dipyridamole","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Ticlopidine","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Urokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Streptokinase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tenecteplase","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rivaroxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Apixaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Edoxaban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dabigatran","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Argatroban","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Bivalirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Heparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Enoxaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Dalteparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tinzaparin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Fondaparinux","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Desirudin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Becaplermin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Omalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eculizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Infliximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Adalimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Certolizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Golimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Etanercept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alemtuzumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Natalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Daclizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Efalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Muromonab-CD3","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Belimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eculizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Infliximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Adalimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Certolizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Golimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Etanercept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alemtuzumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Natalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Daclizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Efalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Muromonab-CD3","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Belimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eculizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Infliximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Adalimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Certolizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Golimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Etanercept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alemtuzumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Natalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Daclizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Efalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Muromonab-CD3","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Belimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eculizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Infliximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Adalimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Certolizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Golimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Etanercept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alemtuzumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Natalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Daclizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Efalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Muromonab-CD3","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Belimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eculizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Infliximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Adalimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Certolizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Golimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Etanercept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alemtuzumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Natalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Daclizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Efalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Muromonab-CD3","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Belimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eculizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Infliximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Adalimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Certolizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Golimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Etanercept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Rituximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Alemtuzumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Natalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Daclizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Efalizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Muromonab-CD3","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Tocilizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Belimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Eculizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Infliximab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Adalimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Certolizumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Golimumab","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Etanercept","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Abatacept","action":"Monitor","effect":"Increased risk of bleeding"}],"commonSideEffects":[],"contraindications":["If you take iron, vitamin B3, blood thinners, or other supplements and drugs, talk to your healthcare provider about ideal dosing schedules with vitamin C.","Taking vitamin B12 and high doses of vitamin C may degrade certain forms of vitamin B12 (such as cyanocobalamin), reducing the amount absorbed in the gut.","While vitamin C is a safe and effective way to enhance iron absorption from foods, Paschal says people with iron-overload conditions (such as hemochromatosis) should avoid high-dose vitamin C supplements, as they may increase the risk of tissue damage or toxicity.","Vitamin C reduces available copper, leading to oxidative stress and potential kidney damage.","taking vitamin C with niacin and a statin may reduce the effectiveness of your cholesterol medication, preventing an increase in HDL cholesterol.","Vitamin C can interact with warfarin, a blood thinner that prevents and treats blood clots, leading to a decrease in warfarin's anticoagulant effect."],"specialPopulations":{"Pregnancy":"The standard of care for treating hepatitis C in a pregnant person is to initiate treatment postpartum, which can start as soon as the person gives birth. Under the guidance of specialists at Northwestern Medicine and Ann & Robert H. Lurie Children’s Hospital of Chicago, an innovative treatment plan is now being offered during pregnancy, allowing the pregnant person to be cured of hepatitis C during the course of prenatal care, which may also substantially mitigate or even eliminate the risk of transmission to the infant. Without treatment, hepatitis C can lead to acute and chronic hepatitis, increasing the risk of liver cancer, liver failure and other conditions. During pregnancy, hepatitis C has been associated with low birthweight, intrahepatic cholestasis of pregnancy and preterm birth. When patients desire treatment, physicians and infectious diseases pharmacists work on obtaining insurance coverage for treatment. Medications are then initiated, which are once-daily pills taken for 8-12 weeks. Lab surveillance is done to monitor the effectiveness of the treatment and to confirm cure.","Geriatric use":"text","Paediatric use":"While infants can clear a hepatitis C virus at a higher rate than adults, if left untested and untreated for several years, it can cause scarring and fibrosis in the liver. Until now, testing in infants was often delayed, but the Northwestern Medicine Women’s Infectious Disease Program now offers testing for infants born to mothers with hepatitis C. The greatest risk of acquiring hepatitis C belongs to people who work with human blood, body fluids or needles; use IV drugs; or have unprotected sex with someone who has hepatitis C. In 2020, guidelines implemented by the United States Preventive Services Task Force recommend all pregnant women be tested for hepatitis C antibodies, and those who test positive undergo further testing and are referred to the Northwestern Medicine Women’s Infectious Disease Program.","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=treatment-c","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:50:16.356052+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:50:22.939348+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:50:16.425080+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=treatment-c","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:50:23.284938+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3350556/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:50:24.447896+00:00"}},"allNames":"treatment c","offLabel":[],"timeline":[],"_dailymed":{"setId":"4dbc521c-2f5f-9736-e063-6294a90ad85d","title":"HERMON JOCK ITCH ANTIFUNGAL TREATMENT CREAM (MICONAZOLE NITRATE 2%) CREAM [BEAUTIVITY LLC]","labeler":""},"aiSummary":"Treatment C, developed by Pfizer Inc., is a marketed drug with a revenue of $63.6B. It is used to treat Indication 1, Indication 2, and Indication 3. The drug's mechanism is not specified. Treatment C has undergone 100 trials and has been the subject of 1002 publications. Its commercial significance is substantial. There are no pipeline developments mentioned.","brandName":"Treatment C","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"Without a clear understanding of the mechanism, it is challenging for healthcare professionals to fully appreciate the drug's effects and potential interactions."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"yoyGrowth":"7%","annualCostUS":"$80,000/yr","genericStatus":"Generic — off-patent","currentRevenue":"","peakSalesEstimate":""},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=treatment-c","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=treatment-c","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:26.121527+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Epclusa","company":"Gilead Sciences","advantage":"Combination of sofosbuvir and velpatasvir, offering a cure for hepatitis C in 12 weeks"},{"name":"Harvoni","company":"Gilead Sciences","advantage":"Combination of sofosbuvir and ledipasvir, offering a cure for hepatitis C in 12 weeks"},{"name":"Mavyret","company":"AbbVie","advantage":"Combination of glecaprevir and pibrentasvir, offering a cure for hepatitis C in 8 weeks"},{"name":"Zepatier","company":"Merck","advantage":"Combination of elbasvir and grazoprevir, offering a cure for hepatitis C in 12 weeks"},{"name":"Vosevi","company":"Gilead Sciences","advantage":"Combination of sofosbuvir, velpatasvir, and voxilaprevir, offering a cure for hepatitis C in 12 weeks"},{"name":"Viekira","company":"AbbVie","advantage":"Combination of dasabuvir, ombitasvir, paritaprevir, and ritonavir, offering a cure for hepatitis C in 12 weeks"}],"genericName":"treatment-c","indications":{"approved":[{"name":"Indication 1","regulator":"FDA"},{"name":"Indication 2","regulator":"FDA"},{"name":"Indication 3","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07042945","phase":"PHASE1","title":"MK-4646 Multiple Dose Trial in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-4646-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-07-09","conditions":"HIV Infection","enrollment":28},{"nctId":"NCT04929028","phase":"PHASE2","title":"Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-09","conditions":"AIDS-Related Anal Carcinoma, Anal Margin Squamous Cell Carcinoma, Anal Non-Keratinizing Squamous Cell Carcinoma","enrollment":40},{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT05600894","phase":"PHASE2","title":"Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts","enrollment":132},{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260},{"nctId":"NCT06356610","phase":"NA","title":"Pharmacokinetic and Subjective Effects of Heated Tobacco Products","status":"COMPLETED","sponsor":"Altria Client Services LLC","startDate":"2024-02-06","conditions":"Tobacco Use","enrollment":80},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":"Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia","enrollment":153},{"nctId":"NCT03739411","phase":"PHASE1","title":"Hyperpolarized Imaging in Diagnosing Participants With Glioma","status":"RECRUITING","sponsor":"Susan Chang","startDate":"2015-12-09","conditions":"Glioma","enrollment":140},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT07024784","phase":"PHASE2","title":"A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-07-30","conditions":"Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer","enrollment":377},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":"B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Down Syndrome","enrollment":6720},{"nctId":"NCT01468896","phase":"PHASE1, PHASE2","title":"Cetuximab and Recombinant Interleukin-12 in Treating Patients With Squamous Cell Carcinoma of the Head and Neck That is Recurrent, Metastatic, or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-10-26","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma","enrollment":23},{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT07497269","phase":"NA","title":"Conventional vs Pulsed RF in Coccydynia","status":"NOT_YET_RECRUITING","sponsor":"Adana City Training and Research Hospital","startDate":"2026-04-01","conditions":"Back Pain","enrollment":90},{"nctId":"NCT06948448","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2025-11-18","conditions":"Colorectal Cancer","enrollment":144},{"nctId":"NCT05490771","phase":"PHASE2","title":"Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-06-20","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphatic System Neoplasm","enrollment":35},{"nctId":"NCT07496008","phase":"","title":"Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population","status":"NOT_YET_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-03-25","conditions":"Isavuconazole, Invasion Pulmonary Mycosis","enrollment":150},{"nctId":"NCT07116109","phase":"NA","title":"Neuromodulation + Prolonged Exposure Therapy: Evaluation of a Technology-Enhanced, Integrated Treatment for Pain and PTSD","status":"RECRUITING","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2025-07-01","conditions":"Chronic Pain, Post Traumatic Stress Disorder (PTSD)","enrollment":146},{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":"Alveolar Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma","enrollment":325},{"nctId":"NCT05564377","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-04-07","conditions":"Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8","enrollment":2900},{"nctId":"NCT07463807","phase":"PHASE1, PHASE2","title":"Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-26","conditions":"Recurrent Multiple Myeloma, Refractory Multiple Myeloma","enrollment":162},{"nctId":"NCT02772003","phase":"PHASE1","title":"DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-06","conditions":"Chronic Hepatitis, Hepatitis C Infection, Hepatocellular Carcinoma","enrollment":33},{"nctId":"NCT03049462","phase":"PHASE1","title":"The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment With Beta3-Adrenergic Receptor Agonists","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-03-13","conditions":"Polycystic Ovary Syndrome","enrollment":100},{"nctId":"NCT04847063","phase":"PHASE1","title":"Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-19","conditions":"Peritoneal Mesothelioma, Peritoneal Carcinomatosis, Ovarian Cancer","enrollment":60},{"nctId":"NCT01306019","phase":"PHASE1, PHASE2","title":"Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-09-25","conditions":"X-linked Severe Combined Immunodeficiency (XSCID)","enrollment":40},{"nctId":"NCT06917911","phase":"PHASE2","title":"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-18","conditions":"Core Binding Factor Acute Myeloid Leukemia","enrollment":162},{"nctId":"NCT05562427","phase":"NA","title":"Program for Fully Understanding Eating and Lifestyle Change (FUEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Miriam Hospital","startDate":"2022-10-31","conditions":"Obesity","enrollment":150},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":"Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type","enrollment":94},{"nctId":"NCT00326482","phase":"","title":"Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-07-31","conditions":"Liver Fibrosis, Steatohepatitis, Elevated Transaminases","enrollment":127},{"nctId":"NCT06453525","phase":"","title":"PrediSuisse: Automatized Assessment of Difficult Airway","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire Vaudois","startDate":"2025-01-01","conditions":"Anesthesia, Intubation; Difficult or Failed, Airway Complication of Anesthesia","enrollment":1800},{"nctId":"NCT06744504","phase":"PHASE3","title":"Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-10","conditions":"AML, RUNX1-RUNX1T1 Fusion Protein Expression","enrollment":300},{"nctId":"NCT05308446","phase":"PHASE2","title":"Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-19","conditions":"Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8","enrollment":84},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT05554393","phase":"PHASE2","title":"Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-13","conditions":"Acute Myeloid Leukemia","enrollment":153},{"nctId":"NCT04071236","phase":"PHASE1, PHASE2","title":"Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-10-14","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes","enrollment":90},{"nctId":"NCT04628767","phase":"PHASE2, PHASE3","title":"Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-12","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":249},{"nctId":"NCT07496957","phase":"NA","title":"Preserflo MicroShunt Versus Trabeculectomy","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2026-03-01","conditions":"GLAUCOMA 1, OPEN ANGLE, D (Disorder)","enrollment":100},{"nctId":"NCT07431151","phase":"NA","title":"Effects of Intensive Virtual Reality-Based Balance and Gait Training on Activity Performance and Quality of Life in Subacute Stroke Patients","status":"RECRUITING","sponsor":"Ankara Yildirim Beyazıt University","startDate":"2026-02-01","conditions":"Stroke","enrollment":48},{"nctId":"NCT03919695","phase":"NA","title":"Development of an Intervention to Reduce Heavy Drinking and Improve HIV Care Engagement Among Fisherfolk in Uganda","status":"COMPLETED","sponsor":"San Diego State University","startDate":"2021-01-11","conditions":"Alcohol Use Disorder, HIV-infection/Aids","enrollment":160},{"nctId":"NCT07498322","phase":"NA","title":"Chicago Data-driven Opioid Use Disorder Screening, Engagement, Treatment and Planning System","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2026-06-01","conditions":"Opiod Use Disorder","enrollment":271031},{"nctId":"NCT07497191","phase":"","title":"AMH Dynamic Changes to Predict Ovarian Reserve in Perimenopausal Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shengjing Hospital","startDate":"2026-03-05","conditions":"Breast Cancer, Perimenopause, Ovarian Reserve","enrollment":300},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT07494513","phase":"NA","title":"Milieu Teaching-AV: Adaptation of Milieu Teaching That Encourages Looking to the Mouth","status":"NOT_YET_RECRUITING","sponsor":"Father Flanagan's Boys' Home","startDate":"2026-04","conditions":"Autism, Autism Spectrum Disorder, Autism, Susceptibility to, 6","enrollment":60},{"nctId":"NCT04190550","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-04","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome","enrollment":24},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":"DOCK8 Deficiency","enrollment":70},{"nctId":"NCT07012044","phase":"PHASE1","title":"A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-30","conditions":"Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":47},{"nctId":"NCT02392429","phase":"PHASE2","title":"FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-04-20","conditions":"Acute Myeloid Leukemia","enrollment":87},{"nctId":"NCT06980428","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-27","conditions":"Healthy Participants, Dyslipidemia","enrollment":136},{"nctId":"NCT07363694","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-11","conditions":"Moderate to Severe Chronic Obstructive Pulmonary Disease","enrollment":1156},{"nctId":"NCT07494474","phase":"","title":"Risk Assessment of Pancreatic Islet Autoimmunity in Patients With AITD","status":"NOT_YET_RECRUITING","sponsor":"Nanjing Medical University","startDate":"2026-08-31","conditions":"Autoimmune Thyroid Disease","enrollment":834},{"nctId":"NCT03783000","phase":"PHASE1","title":"A Study in Healthy Men to Measure the Amount of BI 425809 in the Blood When Taken as a Tablet","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-01-15","conditions":"Healthy","enrollment":6},{"nctId":"NCT04340843","phase":"PHASE2","title":"Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-09-08","conditions":"Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma","enrollment":19},{"nctId":"NCT04167969","phase":"PHASE1","title":"The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-02-17","conditions":"Prostate Cancer","enrollment":16},{"nctId":"NCT07396688","phase":"NA","title":"Comparative Evaluation of the Effects of Calcium Hydroxide and BIO-C Temp Medicaments on Postoperative Pain in Patients Undergoing Endodontic Treatment: a Clinical Study","status":"RECRUITING","sponsor":"Ankara University","startDate":"2026-03-25","conditions":"Postoperative Pain, Medicaments Substances in Therapeutic Use, Calcium Hydroxide","enrollment":60},{"nctId":"NCT07236554","phase":"NA","title":"Blood Flow Restriction Training Versus Mulligan Technique in Treatment of Lateral Epicondylitis","status":"COMPLETED","sponsor":"Cairo University","startDate":"2025-09-15","conditions":"Lateral Epicondylitis (Tennis Elbow)","enrollment":45},{"nctId":"NCT06312176","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-04-14","conditions":"Breast Neoplasms","enrollment":1200},{"nctId":"NCT04164199","phase":"PHASE3","title":"Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeOne Medicines","startDate":"2019-12-19","conditions":"Advanced Malignancies","enrollment":404},{"nctId":"NCT02180867","phase":"PHASE2, PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":"Alveolar Soft Part Sarcoma, Angiomatoid Fibrous Histiocytoma, Atypical Fibroxanthoma","enrollment":140},{"nctId":"NCT04671667","phase":"PHASE2","title":"Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-27","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma","enrollment":188},{"nctId":"NCT05272384","phase":"PHASE1","title":"Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-03","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma","enrollment":32},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":"Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":97},{"nctId":"NCT01861314","phase":"PHASE1","title":"Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-03","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia","enrollment":15},{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT07495228","phase":"NA","title":"Cognitive Processing Therapy for Childbirth-Related Post-Traumatic Stress Disorder","status":"NOT_YET_RECRUITING","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2026-04-01","conditions":"Childbirth-Related Posttraumatic Stress Disorder, Childbirth-related Trauma","enrollment":29},{"nctId":"NCT03983824","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-05-05","conditions":"Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT06672146","phase":"PHASE2","title":"Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-05-16","conditions":"Acute Myeloid Leukemia","enrollment":93},{"nctId":"NCT03604991","phase":"PHASE2, PHASE3","title":"Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-03","conditions":"Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8","enrollment":278},{"nctId":"NCT06561685","phase":"PHASE1","title":"A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2024-09-19","conditions":"Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer","enrollment":340},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","enrollment":348},{"nctId":"NCT01627041","phase":"PHASE2","title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-16","conditions":"Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":178},{"nctId":"NCT06568172","phase":"PHASE3","title":"Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-02-18","conditions":"Eyelid Squamous Cell Carcinoma, Recurrent Eyelid Squamous Cell Carcinoma, Recurrent Skin Acantholytic Squamous Cell Carcinoma","enrollment":420},{"nctId":"NCT05554419","phase":"PHASE2","title":"Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-07-01","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising From Previous Myeloproliferative Neoplasm","enrollment":184},{"nctId":"NCT06726148","phase":"PHASE1, PHASE2","title":"Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-03","conditions":"Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors","enrollment":280},{"nctId":"NCT07437950","phase":"PHASE2","title":"Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-14","conditions":"Acute Myeloid Leukemia","enrollment":126},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":"Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8","enrollment":1875},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT05012033","phase":"","title":"Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2023-04-12","conditions":"Thyroid Eye Disease, Vasculitis, COPD Exacerbation Acute","enrollment":120},{"nctId":"NCT06385119","phase":"PHASE1","title":"A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.","status":"COMPLETED","sponsor":"Fore Biotherapeutics","startDate":"2024-04-24","conditions":"Healthy Participants","enrollment":28},{"nctId":"NCT07043725","phase":"PHASE3","title":"A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.","startDate":"2025-09-15","conditions":"HER2-positive Breast Cancer","enrollment":544},{"nctId":"NCT05488067","phase":"PHASE4","title":"Atorvastatin Therapy on Xanthoma in Alagille Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2022-03-22","conditions":"Alagille Syndrome, Atorvastatin, Xanthoma","enrollment":15},{"nctId":"NCT06778122","phase":"NA","title":"In-Bedroom Renewed Air as Anti-inflammatory Adjuvant Therapy in Cancer Survivors","status":"RECRUITING","sponsor":"University College, London","startDate":"2026-01-23","conditions":"Cancer Survivors, Cardiotoxicity, Cardiovascular Toxicity Induced by Antitumoral Drugs","enrollment":10},{"nctId":"NCT04482309","phase":"PHASE2","title":"A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-08-18","conditions":"Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer","enrollment":477},{"nctId":"NCT05886049","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-20","conditions":"Acute Myeloid Leukemia With KMT2A Rearrangement, Acute Myeloid Leukemia With NPM1 Mutation","enrollment":28},{"nctId":"NCT00217737","phase":"PHASE3","title":"Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2005-09-06","conditions":"Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7","enrollment":2431},{"nctId":"NCT05307705","phase":"PHASE1","title":"A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-05-11","conditions":"Breast Cancer","enrollment":193},{"nctId":"NCT07153497","phase":"PHASE2","title":"Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-27","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":132},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT04450043","phase":"NA","title":"The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-08-01","conditions":"Non Small Cell Lung Cancer, Small-cell Lung Cancer, Mesothelioma","enrollment":21},{"nctId":"NCT06589804","phase":"PHASE3","title":"Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-27","conditions":"Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Squamous Cell Carcinoma","enrollment":158},{"nctId":"NCT04660344","phase":"PHASE3","title":"A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-03","conditions":"Muscle-invasive Bladder Cancer","enrollment":761},{"nctId":"NCT05554406","phase":"PHASE2","title":"Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-25","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":335},{"nctId":"NCT06507904","phase":"PHASE1","title":"A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-09-15","conditions":"Healthy","enrollment":52},{"nctId":"NCT05601440","phase":"PHASE2","title":"Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer","status":"RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2023-06-13","conditions":"Breast Cancer","enrollment":484},{"nctId":"NCT06577441","phase":"PHASE2","title":"Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-12","conditions":"Myelodysplastic Syndrome","enrollment":54},{"nctId":"NCT06102902","phase":"PHASE1","title":"Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-05","conditions":"Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma","enrollment":30},{"nctId":"NCT07042295","phase":"PHASE2","title":"Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-03-23","conditions":"Locally Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma","enrollment":86},{"nctId":"NCT04297683","phase":"PHASE2, PHASE3","title":"HEALEY ALS Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Merit E. Cudkowicz, MD","startDate":"2020-06-14","conditions":"Amyotrophic Lateral Sclerosis","enrollment":1500},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":"Contact With or Exposure to Human Immunodeficiency Virus","enrollment":1500},{"nctId":"NCT02193282","phase":"PHASE3","title":"Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-02-11","conditions":"Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7","enrollment":390}],"_emaApprovals":[{"date":"","name":"Treatment C","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL3350556","moleculeType":"Small molecule","molecularWeight":"1112.80"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL3350556"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":1005,"therapeuticAreas":["Other"],"_revenueScrapedAt":"2026-03-31 10:38:15.640357+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"_investorTranscripts":{"url":"https://www.pfizer.com/investors/presentations","source":"Investor transcripts","mentions":["Treatment Choices","Treatment Choices"]},"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"discontinued","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":3,"visitCount":3,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"pricingByCountry":[{"country_code":"US","currency":"USD","price_amount":"80000.00","price_per":"year","price_type":"annual_list","annual_cost_usd":null,"reimbursement_status":null}],"trialStats":{"total":21,"withResults":6},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:50:26.121527+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}